Myriad Genetics to Announce Fiscal Fourth Quarter and Fiscal Year 2012 Results on Tuesday, August 14, 2012

Posted: July 25, 2012 at 3:12 pm

SALT LAKE CITY, July 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN) today announced that it will issue financial results for the fourth fiscal quarter and fiscal year 2012 following the close of market on Tuesday, August 14, 2012.

The Company will also host a conference call on Tuesday, August 14, 2012 at 4:30 P.M. Eastern to review the financial results. Participating on the call will be: Peter Meldrum, President and Chief Executive Officer, Mark Capone, President of Myriad Genetic Laboratories, Inc. and Jim Evans, Chief Financial Officer.

To listen to the call, interested parties may dial 800-403-7802 or 303-223-2680. All callers will be asked to reference reservation number 21600202.

The conference call will also be available through a live webcast at http://www.myriad.com.

A replay of the call will be available two hours after the end of the call for seven days and may be accessed by dialing 800-633-8284 or 402-977-9140 and entering reservation number 21600202.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient's lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

See the rest here:
Myriad Genetics to Announce Fiscal Fourth Quarter and Fiscal Year 2012 Results on Tuesday, August 14, 2012

Related Post

Comments are closed.

Archives